While therapies exist to address some symptoms of schizophrenia, there are currently no approved medications for cognitive impairment associated with schizophrenia (CIAS). We’re researching potential ways to change this.
That’s why we’re conducting the TALLY clinical trial. We want to see if a new investigational drug could potentially address this unmet need, and impact things like memory, attention and problem solving.
Do you have a patient or know someone who might want to participate in this research? Are you living with schizophrenia and want to know more? See who could qualify by taking our short eligibility test.